Modulation by dietary salt of verapamil disposition in humans. 1998

D Darbar, and M F Fromm, and S Dell'Orto, and R B Kim, and H K Kroemer, and M Eichelbaum, and D M Roden
Departments of Medicine and Pharmacology, Vanderbilt University School of Medicine, Nashville, TN, USA.

BACKGROUND The intestine is an increasingly well-recognized site of first-pass drug metabolism. In this study, we determined the influence of dietary salt on the steady-state disposition of verapamil, a drug that undergoes extensive first-pass metabolism. RESULTS Eight normal volunteers received 120 mg of racemic verapamil orally twice a day for 21 days. The disposition kinetics of verapamil enantiomers were determined after coadministration of intravenous deuterated verapamil with the morning oral dose on days 7, 14, and 21. Each study day was preceded by 7 days on a fixed-salt diet: in 5 subjects, the initial study was conducted during a low-salt (10 mEq/d) diet, the second study during a high-salt (400 mEq/d) diet, and the third during a low-salt diet, whereas in the other 3 subjects, the sequence of diets was reversed. Plasma concentrations of both unlabeled enantiomers (ie, from oral therapy) were significantly (P<0.05) lower during the high-salt phase (eg, mean area under the time-concentration curve [0 to 12 hours] for S-verapamil: 7765+/-2591 ng. min. mL-1 [high salt] versus 12 514+/-3527 ng. min. mL-1 [low salt], P<0.05). Peak plasma concentrations were significantly lower and the extent of PR interval prolongation significantly blunted with the high-salt diet. In contrast, data with labeled drug (ie, reflecting the intravenous route) were nearly identical for the 2 diets. CONCLUSIONS These data indicate that a clinically important component of presystemic drug disposition occurs at the prehepatic (presumably intestinal) level and is sensitive to dietary salt.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008297 Male Males
D003903 Deuterium The stable isotope of hydrogen. It has one neutron and one proton in the nucleus. Deuterons,Hydrogen-2,Hydrogen 2
D004039 Diet, Sodium-Restricted A diet which contains very little sodium chloride. It is prescribed by some for hypertension and for edematous states. (Dorland, 27th ed) Diet, Low-Salt,Diet, Low-Sodium,Diet, Salt-Free,Diet, Low Salt,Diet, Low Sodium,Diet, Salt Free,Diet, Sodium Restricted,Diets, Low-Salt,Diets, Low-Sodium,Diets, Salt-Free,Diets, Sodium-Restricted,Low-Salt Diet,Low-Salt Diets,Low-Sodium Diet,Low-Sodium Diets,Salt-Free Diet,Salt-Free Diets,Sodium-Restricted Diet,Sodium-Restricted Diets
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D014700 Verapamil A calcium channel blocker that is a class IV anti-arrhythmia agent. Iproveratril,Calan,Cordilox,Dexverapamil,Falicard,Finoptin,Isoptin,Isoptine,Izoptin,Lekoptin,Verapamil Hydrochloride,Hydrochloride, Verapamil

Related Publications

D Darbar, and M F Fromm, and S Dell'Orto, and R B Kim, and H K Kroemer, and M Eichelbaum, and D M Roden
July 1988, The Journal of pharmacology and experimental therapeutics,
D Darbar, and M F Fromm, and S Dell'Orto, and R B Kim, and H K Kroemer, and M Eichelbaum, and D M Roden
March 1988, The Journal of pharmacology and experimental therapeutics,
D Darbar, and M F Fromm, and S Dell'Orto, and R B Kim, and H K Kroemer, and M Eichelbaum, and D M Roden
April 2008, Xenobiotica; the fate of foreign compounds in biological systems,
D Darbar, and M F Fromm, and S Dell'Orto, and R B Kim, and H K Kroemer, and M Eichelbaum, and D M Roden
September 1976, Cardiovascular research,
D Darbar, and M F Fromm, and S Dell'Orto, and R B Kim, and H K Kroemer, and M Eichelbaum, and D M Roden
April 2004, Hypertension (Dallas, Tex. : 1979),
D Darbar, and M F Fromm, and S Dell'Orto, and R B Kim, and H K Kroemer, and M Eichelbaum, and D M Roden
April 2016, The Journal of nutrition,
D Darbar, and M F Fromm, and S Dell'Orto, and R B Kim, and H K Kroemer, and M Eichelbaum, and D M Roden
January 2018, Journal of nutritional science and vitaminology,
D Darbar, and M F Fromm, and S Dell'Orto, and R B Kim, and H K Kroemer, and M Eichelbaum, and D M Roden
June 1985, Clinical pharmacology and therapeutics,
D Darbar, and M F Fromm, and S Dell'Orto, and R B Kim, and H K Kroemer, and M Eichelbaum, and D M Roden
January 1984, Journal of cardiovascular pharmacology,
D Darbar, and M F Fromm, and S Dell'Orto, and R B Kim, and H K Kroemer, and M Eichelbaum, and D M Roden
October 2000, The American journal of clinical nutrition,
Copied contents to your clipboard!